Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implementation RSV Immunization Study (IRIS)
2025-521801-42-00Phase 4Authorised
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nirsevimab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by National Institute for Public Health and the Environment. Planned start Jul 2025; status: authorised.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2025-521801-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521801-42-00.